166P Outcomes by Baseline Liver Function in EMERALD-1: A Phase III, Randomised, Placebo (Pbo)-Controlled Study of Durvalumab (D) with or Without Bevacizumab (B) with Transarterial Chemoembolisation (TACE) in Participants (pts) with Embolisation-Eligible Unresectable Hepatocellular Carcinoma (Uhcc)